Burnham Institute to collaborate in NCI funded Center of Cancer Nanotechnology Excellence
3rd Oct 2005, 15:00 GMT
As part of the newly funded Center of Cancer Nanotechnology Excellence (CCNE) established at the University of California by the National Cancer Institute (NCI Dr. Erkki Ruoslahti, Distinguished Professor at the Institute, will join a team of world class nanoengineers to integrate "homing" functionality into nanodevices, or so called "mother ships," capable of delivering diagnostic or therapeutic cargo to cancer blood vessels. [The project will bring $6.8 million the Institute over the next five years.]
Burnham Institute to collaborate in NCI funded Center of Cancer Nanotechnology Excellence related news:
- $16 million grant advances nanomedicine at Washington University — EurekAlert! - Biology
- Assembling nanodevices capable of targeting tumor vasculature — Medical News Today RSS/XML Feed
- Northwestern receives major award for nanotechnology cancer center — EurekAlert! - Medicine and Health
- Caltech Gets Nanosystems Funding — socalTECH.com - Southern California High Tech News
- Fertile Hope: Cleveland Clinic Taussig Cancer Center Recognized as the First Fertile Hope Center of Excellence — Market Wire - Financial Services
- Cleveland Clinic Taussig Cancer Center Recognized as the First Fertile Hope Center of Excellence — ArriveNet : Press Releases
- The Burnham Institute Board Elects New Members, New Chairman — Rednova News - Health
- Drexel, Penn, and Ben Franklin Technology Partners of Southeastern PA Form Nanotechnology Commercialization Group Through the Nanotechnology Institute — ArriveNet : Press Releases
- Taiwan focusing on nanotechnology; how about nanoethics? — DigiTimes: IT news from Asia
- AHD, new cancer centre — AME Info News - Healthcare
Latest news from EurekAlert! - Cancer:
- Targeted cancer drugs may work by disrupting balance of cellular signals
- Studies examine colorectal cancer screening rates
- Higher red meat intake may increase risk for certain breast cancers
- U-M researchers use nanoparticles to target brain cancer
- 'Trojan Horse' agent halts bone metastasis in mice
- Increased patient demand for prostate test has serious implications for cancer services
- Novel regulatory mechanism identified for key tumor suppressor p53